A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

What is the purpose of this trial?

A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) who experienced disease progression during or following two lines of treatment.

Eligible patients will be assigned to one of several treatment arms.



F. Hoffman-La Roche Ltd

Start Date: 10/03/2018

End Date: 04/01/2020

Last Updated: 12/02/2018

Study HIC#: 2000023122

Get Involved

For more information about this study, contact:
Kirsten Dooley
+1 203-764-8412
kirsten.dooley@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image